Canaccord Genuity has downgraded Exact Sciences Corp (EXAS) to Hold from Buy as of November 24, 2025. The current share price stands at $101.45.
This downgrade highlights increased caution regarding the company's outlook. Analysts may have concerns about competitive pressures, market conditions, or execution risks that could affect Exact Sciences' performance.
Exact Sciences is a biotechnology firm headquartered in Madison, Wisconsin, focusing on cancer screening and diagnostics. The company employs 6,900 full-time staff and offers a portfolio of products aimed at early cancer detection and treatment guidance. Its flagship product, the Cologuard test, is a non-invasive, stool-based screening test for colorectal cancer.
As of November 1, 2025, the analyst consensus for Exact Sciences is a Buy, with 12 Strong Buy, 14 Buy, and 4 Hold ratings among 30 analysts. However, recent downgrades from several firms, including Benchmark and Jefferies, indicate a shift in sentiment.
Upcoming earnings are scheduled for August 4, 2026, with an estimated EPS of $0.12 and revenue of $935.7 million. The company's market capitalization is currently $12.7 billion, with a trailing twelve-month EPS of -5.42.